Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL

Iain B. McInnes,¹ Philip J. Mease,² Yoshiya Tanaka,³ Frank Behrens,⁴ Laure Gossec,⁵ M. Elaine Husni,⁶ Lars E. Kristensen,⁷ Richard B. Warren,^{8,9} Barbara Ink,¹⁰ Rajan Bajracharya,¹⁰ Jason Coarse,¹¹ Jason Eells,¹⁰ Alice B. Gottlieb¹²

Objective

To report the efficacy and safety of bimekizumab (BKZ) to Week 52 from the phase 3 study BE OPTIMAL in biologic disease-modifying antirheumatic drug-naïve patients with psoriatic arthritis (PsA), with or without concomitant methotrexate.

Background

- Given the chronic nature of PsA, understanding long-term efficacy and safety of biologic monotherapy or therapy in combination with ongoing methotrexate (MTX) is of interest. Studies have shown that tumor necrosis factor inhibitors may have lower efficacy without MTX (– MTX) than with MTX (+ MTX).¹
- Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has shown efficacy and tolerability to 52 weeks in patients with PsA who are biologic disease-modifying antirheumatic drug (bDMARD)-naïve.²

Methods

- BE OPTIMAL (NCT03895203) comprised a 16-week double-blind, placebo (PBO)-controlled period and a 36-week active treatment-blind period.
- Patients were randomized 3:2:1 to subcutaneous BKZ 160 mg every 4 weeks (Q4W), placebo (with switch to BKZ 160 mg Q4W at Week 16) or reference arm (adalimumab [ADA] 40 mg Q2W); the study was not powered for statistical comparisons of ADA to BKZ or PBO.
- Patients generally could not adjust their background medication, including MTX usage, during the 16-week PBO-controlled period. Efficacy and safety were evaluated by concomitant MTX use at baseline.
- Missing data were imputed using non-responder imputation (discrete) or multiple imputation (continuous).

Results

Baseline patient demographics and disease characteristics

770/852 (90.4%) patients completed Week 52 (+ MTX: 458/497 [92.2%]; – MTX: 312/355 [87.9%]), including 9 not on randomized treatment (+ MTX: 4; – MTX: 5). Baseline characteristics were generally similar for +/- MTX patient subgroups (Table 1).

Efficacy to Week 52

- To Week 52, the proportions of BKZ-randomized patients who achieved ≥50% improvement in American College of Rheumatology response criteria (ACR50), complete skin clearance (100% improvement in Psoriasis Area and Severity Index) and minimal disease activity (MDA) were similar regardless of baseline MTX use.
- Fewer patients receiving ADA MTX achieved ACR50 or MDA at Week 52 compared with the ADA + MTX group (Figure 1).
- Other Week 52 efficacy responses on BKZ were generally of a similar magnitude +/- MTX (Table 2).


Safety to Week 52

- To Week 52, the proportion of patients with ≥1 treatment-emergent adverse event (TEAE) was similar for BKZ regardless of +/- MTX. More patients receiving ADA MTX had ≥1 TEAE compared with the ADA + MTX subgroup.
- To Week 52, rates of the most frequent TEAEs were similar between +/- MTX on BKZ, and BKZ was well tolerated regardless of MTX (**Table 3**).

Conclusions

Bimekizumab treatment demonstrated consistent clinical efficacy across disease manifestations to Week 52 in bDMARD-naïve patients with PsA, irrespective of concomitant MTX. Bimekizumab was well tolerated in patients with PsA with or without MTX.

Summary



*The study was not powered for statistical comparisons of ADA to BKZ or PBO, or + MTX and – MTX subgroups.

arm (ADA)

Bimekizumab was well tolerated in patients with active PsA with or without MTX

Table 1 Baseline characteristics +/- MTX

	PBO/BKZ 160 mg Q4W N=281		BKZ 160 mg Q4W N=431		Reference arm (ADA 40 mg Q2W) N=140	
	+ MTX n=163	– MTX n=118	+ MTX n=252	– MTX n=179	+ MTX n=82	– MTX n=58
Age , years, mean (SD)	48.2 (11.5)	49.3 (12.1)	47.8 (12.6)	49.6 (12.4)	49.2 (11.7)	48.8 (14.2)
Male , n (%)	72 (44.2)	55 (46.6)	122 (48.4)	79 (44.1)	41 (50.0)	30 (51.7)
BMI , kg/m ² , mean (SD)	29.4 (6.1)	29.9 (6.0)	29.1 (6.5)	29.4 (7.2)	28.4 (5.7)	28.4 (6.2)
Time since first diagnosis of PsA, years, mean (SD)	5.4 (6.2)	6.0 (7.0)ª	5.8 (7.3) ^a	6.2 (7.3)b	5.9 (6.2)	6.5 (7.6) ^c
≥3% BSA affected by psoriasis, n (%)	83 (50.9)	57 (48.3)	126 (50.0)	91 (50.8)	37 (45.1)	31 (53.4)
PASI score,d mean (SD)	7.6 (5.3)	8.4 (6.1)	7.7 (6.4)	8.8 (7.4)	9.6 (8.1)	7.3 (6.8)
TJC (of 66) , mean (SD)	16.4 (12.3)	18.0 (12.7)	16.6 (11.8)	17.1 (11.8)	17.8 (13.1)	17.2 (13.1)
SJC (of 68) , mean (SD)	10.0 (7.8)	8.8 (6.5)	9.1 (6.4)	8.8 (5.9)	9.8 (7.4)	9.4 (6.7)
Enthesitis,e n (%)	36 (22.1)	34 (28.8)	82 (32.5) ^f	61 (34.1) ^c	18 (22.0)°	18 (31.0)
LEI score,g mean (SD)	2.8 (1.6)	3.0 (1.5)	2.4 (1.4) ^f	2.6 (1.5)°	2.2 (1.6)°	2.3 (1.6)
Dactylitis, h n (%)	22 (13.5)	11 (9.3)	28 (11.1) ^b	28 (15.6)°	5 (6.1)°	6 (10.3)
LDI score, mean (SD)	46.1 (36.6)	49.9 (50.6)	38.2 (32.0)b	55.3 (69.6)°	54.1 (37.3)°	46.0 (29.8)
Nail psoriasis, n (%)	92 (56.4)	64 (54.2)	146 (57.9)b	98 (54.7)°	42 (51.2)	33 (56.9)
mNAPSI score, ^k mean (SD)	4.1 (2.2)	3.8 (2.0)	4.0 (2.4)b	4.2 (2.5)°	3.7 (2.2)	3.8 (2.4)
PGA-PsA, mean (SD)	60.1 (23.7)	56.5 (23.1)	53.1 (23.5)°	56.3 (23.3)	57.3 (21.8)	56.7 (22.0)
HAQ-DI, mean (SD)	0.90 (0.60)	0.88 (0.62)	0.78 (0.59)°	0.87 (0.58)	0.91 (0.55)	0.79 (0.53)

Randomized set. ^aData missing for two patients; ^bData missing for six patients; ^cData missing for one patient; ^dIn patients with psoriasis involving ≥3% BSA at baseline; ^ePatients with LEI >0; ^fData missing for five patients; ^gIn patients with enthesitis at baseline; ^hPatients with LDI >0; ^fIn patients with dactylitis at baseline; ^fPatients with mNAPSI >0; ^fIn patients with nail psoriasis at baseline


Reference Arm


Table 2 Week 52 efficacy endpoints for patients +/- MTX (NRI and MI)

	Q4W N=281 BKZ 160 mg Q4W N=431		(ADA 40 mg Q2W) N=140			
Endpoint	+ MTX n=163	– MTX n=118	+ MTX n=252	– MTX n=179	+ MTX n=82	– MTX n=58
ACR20 [NRI], n (%)	113 (69.3)	78 (66.1)	184 (73.0)	123 (68.7)	65 (79.3)	37 (63.8)
ACR50 [NRI], n (%)	87 (53.4)	62 (52.5)	137 (54.4)	98 (54.7)	46 (56.1)	24 (41.4)
ACR70 [NRI], n (%)	60 (36.8)	41 (34.7)	96 (38.1)	73 (40.8)	36 (43.9)	17 (29.3)
PASI75 ^a [NRI], n (%)	71 (85.5)	48 (84.2)	105 (83.3)	72 (79.1)	23 (62.2)	22 (71.0)
PASI90 ^a [NRI], n (%)	67 (80.7)	39 (68.4)	89 (70.6)	66 (72.5)	20 (54.1)	21 (67.7)
PASI100 ^a [NRI], n (%)	62 (74.7)	29 (50.9)	77 (61.1)	55 (60.4)	15 (40.5)	18 (58.1)
MDA [NRI], n (%)	87 (53.4)	64 (54.2)	138 (54.8)	99 (55.3)	48 (58.5)	26 (44.8)
VLDA [NRI], n (%)	35 (21.5)	27 (22.9)	72 (28.6)	53 (29.6)	25 (30.5)	14 (24.1)
ACR50+PASI100 ^a [NRI], n (%)	43 (51.8)	22 (38.6)	61 (48.4)	41 (45.1)	12 (32.4)	12 (38.7)
Enthesitis resolution ^b [NRI], n (%)	24 (66.7)	20 (58.8)	53 (64.6)	34 (55.7)	11 (61.1)	10 (55.6)
Dactylitis resolution ^c [NRI], n (%)	18 (81.8)	11 (100.0)	21 (75.0)	24 (85.7)	4 (80.0)	4 (66.7)
HAQ-DI CfB [MI], mean (SE)	-0.37 (0.04)	-0.38 (0.05)	-0.30 (0.03)	-0.38 (0.04)	-0.49 (0.06)	-0.30 (0.08)
Nail psoriasis resolution ^d [NRI], n (%)	68 (73.9)	43 (67.2)	100 (68.5)	60 (61.2)	24 (57.1)	21 (63.6)

Randomized set. aln patients with psoriasis affecting ≥3% BSA at baseline; + MTX: PBO/BKZ n=83, BKZ n=126, ADA n=37; - MTX: PBO/BKZ n=57, BKZ n=91, ADA n=31; bln patients with baseline enthesitis (LEI >0); + MTX: PBO/BKZ n=36, BKZ n=82, ADA n=18; - MTX: PBO/BKZ n=34, BKZ n=61, ADA n=18; cln patients with baseline dactylitis (LDI >0); + MTX: PBO/BKZ n=22, BKZ n=28, ADA n=5; - MTX: PBO/BKZ n=11, BKZ n=28, ADA n=6; dln patients with baseline nail psoriasis (mNAPSI >0); + MTX: PBO/BKZ n=92, BKZ n=146, ADA n=42; - MTX: PBO/BKZ n=98, ADA n=33.

Figure 1 Patients +/- MTX achieving ACR50, PASI100 and MDA to Week 52 (NRI and OC)





Randomized set. ACR50 at Week 16 was the primary endpoint for BE OPTIMAL. ^aN values are NRI/OC at Week 0 and OC at Week 16 and Week 52; ^bIn patients with psoriasis affecting ≥3% BSA at baseline.

Table 3 Safety data to Week 52 for patients +/- MTX

		mg Q4W 702 ^a	Reference Arm (ADA 40 mg Q2W) N=140		
n (%) [EAIR] ^b	+ MTX n=410 PYAR: 355.4	– MTX n=292 PYAR: 247.2	+ MTX n=82 PYAR: 80.7	– MTX n=58 PYAR: 56.1	
Any TEAE	325 (79.3) [219.3]	230 (78.8) [227.6]	63 (76.8) [169.2]	50 (86.2) [298.9]	
Severe TEAEs	13 (3.2)	10 (3.4)	7 (8.5)	2 (3.4)	
Study discontinuation due to TEAEs	10 (2.4) [2.8]	11 (3.8) [4.5]	4 (4.9) [5.1]	3 (5.2) [5.5]	
Drug-related TEAEs	133 (32.4)	91 (31.2)	30 (36.6)	24 (41.4)	
Serious TEAEs	26 (6.3) [7.5]	20 (6.8) [8.4]	7 (8.5) [9.0]	3 (5.2) [5.4]	
Death due to TEAEs	1 (0.2) ^c	0	0	0	
Most frequent adverse events ^d					
Nasopharyngitis	41 (10.0) [12.5]	43 (14.7) [19.4]	3 (3.7) [3.8]	9 (15.5) [18.1]	
Upper respiratory tract infection	34 (8.3) [10.2]	16 (5.5) [6.7]	4 (4.9) [5.1]	4 (6.9) [7.5]	
Urinary tract infection	30 (7.3) [8.7]	13 (4.5) [5.4]	2 (2.4) [2.5]	3 (5.2) [5.5]	
Headache	20 (4.9) [5.9]	21 (7.2) [9.0]	4 (4.9) [5.1]	2 (3.4) [3.6]	
Oral candidiasis ^e	23 (5.6) [6.7]	15 (5.1) [6.2]	1 (1.2) [1.3]	0	
Diarrhea	20 (4.9) [5.8]	16 (5.5) [6.7]	2 (2.4) [2.5]	5 (8.6) [9.5]	
Pharyngitis	21 (5.1) [6.1]	11 (3.8) [4.6]	3 (3.7) [3.8]	0	
Adjudicated MACEf	3 (0.7) [0.9]	1 (0.3) [0.4]	0	0	
Adjudicated definite IBD ⁹	1 (0.2) [0.3]	1 (0.3) [0.4]	0	0	
Malignancies excluding non-melanoma skin ca	ancer				
Colon cancer	1 (0.2) [0.3]	0	0	0	
Chronic lymphocytic leukemia stage 0	0	1 (0.3) [0.4]	0	0	
Papillary thyroid cancer	0	1 (0.3) [0.4]	0	0	
Liver function test changes/enzyme elevations	, n/Nsub (%)				
ALT >3x ULN	11/410 (2.7)	4/291 (1.4)	4/82 (4.9)	3/57 (5.3)	
AST or ALT >3x ULN	16/410 (3.9)	8/291 (2.7)	5/82 (6.1)	4/57 (7.0)	

Safety set. a Includes patients who switched from PBO to BKZ (events after switch only); b EAIRs are reported where available; c Cause of death was a motorcycle accident; unrelated to treatment; d Most frequent adverse events are those occurring in \geq 5% of the BKZ study arm (+/- MTX) reported across all study arms; e All infections were mild or moderate and none were serious; 1 BKZ patient (- MTX) discontinued; f + MTX: 1 case each of myocardial infarction, ischemic stroke and thrombotic cerebral infarction. The case of ischemic stroke was deemed by the investigator to be related to study medication. - MTX: 1 case of cerebrovascular accident; g Both ulcerative colitis; one in a patient with a prior history of IBD (+ MTX), the other de novo (- MTX).

ACR: American College of Rheumatology; ACR20/50/70: American College of Rheumatology response criteria ≥20/50/70% improvement; ADA: adalimumab; ALT: alanine aminotransferase; BMI: body mass index; BSA: body surface area; CfB: change from baseline; EAIR: exposure-adjusted incidence rate; HAQ-DI: Health Assessment Questionnaire-Disability Index; IBD: inflammatory bowel disease; IL: interleukin; LDI: Leeds Dactylitis Index; MACE: major adverse cardiovascular event; MDA: multiple imputation; mNAPSI: modified Nail Psoriasis Severity Index; MTX: methotrexate; NRI: non-responder imputation; OC: observed case; PASI: Psoriasis Area and Severity Index; PSA: psoriatic Arthritis; PSA: psoriatic activity.

Institutions: ¹College of Medical Veterinary and Life Sciences, University of Glasgow, Glasg